Synaps-T™ is our T-cell engager platform designed to precisely modulate the immune synapse for the treatment of autoimmune and antibody-mediated diseases. Rather than maximizing cytotoxicity—as required in oncology—SYNAPS-T™ focuses on controlled synapse formation, enabling selective depletion of pathogenic B cells while minimizing excessive T-cell activation and cytokine release.

Our platform integrates:

• Geometry-engineered engager formats that fine-tune interdomain spacing, epitope positioning, and valency
  
  

• CD3-affinity tuning to adjust activation thresholds for safer engagement
  
  

• Modular, switchable architectures optimized for scalable manufacturability and rapid program expansion
  
  

• A synapse-centric design philosophy informed by structural and biophysical insights from recent advances in T-cell synapse biology
  
  

Together, these features enable the creation of next-generation autoimmune TCEs that balance potency with safety—providing just enough T-cell activation to eliminate autoreactive or plasmablast populations without triggering systemic immune activation.

The result is a versatile platform capable of generating a pipeline of targeted, subcutaneous-ready TCE therapeutics tailored for chronic autoimmune conditions.